Breaking News Instant updates and real-time market news.

KURA

Kura Oncology

$15.55

-0.45 (-2.81%)

16:11
05/07/19
05/07
16:11
05/07/19
16:11

Kura Oncology reports Q1 EPS (37c), consensus (44c)

Cash, cash equivalents and short-term investments totaled $165.5M as of March 31, compared with $179.0M as of December 31, 2018.

  • 07

    May

  • 07

    May

KURA Kura Oncology
$15.55

-0.45 (-2.81%)

12/03/18
PIPR
12/03/18
NO CHANGE
Target $25
PIPR
Overweight
Kura Oncology remains 'favorite smallcap oncology name', says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren kept his Overweight rating and $25 price target on Kura Oncology following the company's update on the development of tipifarnib in highly refractory PTCL patients where a significant association between CXCL12 expression and clinical benefit was observed. The analyst notes that the data were "particularly impressive given the patients' refractory states and importantly, one patient was even able to receive a potentially curative transplant". Van Buren further contends that Kura Oncology is positioned for $500M or more in long-term sales for tipifarnib in HRAS-driven cancers, adding that its "shares are significantly undervalued based on that opportunity alone".
01/07/19
PIPR
01/07/19
NO CHANGE
Target $235
PIPR
Overweight
Piper Jaffray views price paid for Loxo by Eli Lilly as fair
Piper Jaffray analyst Tyler Van Buren views the price of $235 per share paid by Eli Lilly (LLY) for Loxo Oncology (LOXO) as fair. The analyst says the price is near the $250-plus he previously thought was achievable in an acquisition scenario for Loxo. Other names in the precision medicine/oncology space that could be up today as a result of the buyout are Agios Pharmaceuticals (AGIO), ArQule (ARQL), Array BioPharma (ARRY), Blueprint Medicines (BPMC), Kura Oncology (KURA), Mirati Therapeutics (MRTX) and others, Van Buren tells investors in a research note. He raised his price target for Loxo Oncology to $235 from $200 and keeps an Overweight rating on the shares.
01/18/19
PIPR
01/18/19
NO CHANGE
Target $25
PIPR
Overweight
Kura Oncology shares remain 'significantly undervalued,' says Piper Jaffray
Kura Oncology today provided evidence that tipifarnib could be active in patients with no abdominal pain and/or nodal/liver met disease, both of which are associated with high CXCL12 expression, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The analyst estimates tipifarnib's opportunity in the HRAS-driven head and neck squamous cell carcinomas opportunity alone is worth $500M-plus in peak sales. However, with the recent data in CXCL12-driven peripheral T-cell lymphomas presented and now potentially pancreatic cancer, these estimates "could be pushed significantly higher over time," Van Buren adds. He continues to believe Kura Oncology shares are "significantly undervalued" and keeps an Overweight rating on the name with a $25 price target.
04/03/19
PIPR
04/03/19
NO CHANGE
PIPR
Overweight
Piper says Kura's potential patient population for tipifarnib keeps growing
After Kura Oncology presented additional data on tipifarnib, a farnesyltransferase inhibitor/HRAS inhibitor that downregulates expression of CXCL12, Piper Jaffray analyst Tyler Van Buren said the number of potential indications for the drug "continues to multiply" as initial clinical data suggest diffuse large B-cell lymphoma and cutaneous T-cell lymphoma patients could benefit from treatment in addition to the already identified cancer indications. The "broad mechanism of tipifarnib is becoming clear" and the potential patient population keeps growing, "well beyond what investors are currently appreciating," according to Van Buren. He keeps an Overweight rating on Kura shares.

TODAY'S FREE FLY STORIES

EBAY

eBay

$36.56

-0.34 (-0.92%)

16:47
05/20/19
05/20
16:47
05/20/19
16:47
Earnings
eBay VP Kristin Yetto sells over $940K shares of company stock »

eBay VP Kristin Yetto…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

16:45
05/20/19
05/20
16:45
05/20/19
16:45
General news
Fed's Williams said the Fed has changed its view on the Phillips Curve relationship »

Fed's Williams said…

VNE

Veoneer

$18.89

0.02 (0.11%)

16:43
05/20/19
05/20
16:43
05/20/19
16:43
Syndicate
Veoneer files to sell $350M of common stock, $150M of convertible senior notes »

Veoneer announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    Jun

VYGR

Voyager Therapeutics

$21.87

-0.28 (-1.26%)

16:36
05/20/19
05/20
16:36
05/20/19
16:36
Hot Stocks
Voyager Therapeutics announces retirement of chief scientific officer Dinah Sah »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jun

OCUL

Ocular Therapeutix

$3.36

-0.1 (-2.89%)

16:35
05/20/19
05/20
16:35
05/20/19
16:35
Hot Stocks
Breaking Hot Stocks news story on Ocular Therapeutix »

Ocular Therapeutix…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

  • 10

    Nov

HI

Hillenbrand

$38.98

0.05 (0.13%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Initiation
Hillenbrand initiated  »

Hillenbrand initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Earnings
Varian Medical cuts FY19 adj. EPS view to $4.55-$4.70 from $4.60-$4.75 »

Consensus $4.70. Backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

MRK

Merck

$78.86

0.15 (0.19%)

16:34
05/20/19
05/20
16:34
05/20/19
16:34
Hot Stocks
Merck announces Phase 3 KEYNOTE-119 trial does not meet OS primary endpoint »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 31

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

16:33
05/20/19
05/20
16:33
05/20/19
16:33
Hot Stocks
Varian to acquire Cancer Treatment Services for $283M »

Varian Medical Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 31

    May

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:33
05/20/19
05/20
16:33
05/20/19
16:33
Hot Stocks
Nordson CEO says 'continue to forecast organic growth' for 2019 »

CEO Michael Hilton…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:32
05/20/19
05/20
16:32
05/20/19
16:32
Hot Stocks
Breaking Hot Stocks news story on Nordson »

Nordson reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

REGN

Regeneron

$302.51

-2.3 (-0.75%)

, NVS

Novartis

$82.02

-0.7 (-0.85%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Initiation
Regeneron, Novartis, Sanofi initiated at Credit Suisse »

Regeneron initiated with…

REGN

Regeneron

$302.51

-2.3 (-0.75%)

NVS

Novartis

$82.02

-0.7 (-0.85%)

SNY

Sanofi

$41.40

-0.53 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 23

    May

  • 31

    May

  • 14

    Jun

  • 26

    Jun

TMO

Thermo Fisher

$263.13

1.44 (0.55%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Hot Stocks
Thermo Fisher to invest $50M to expand bioproduction capabilities »

Thermo Fisher announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 31

    May

  • 02

    Dec

NDSN

Nordson

$130.42

-4.8 (-3.55%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Earnings
Nordson reports Q2 adjusted EPS $1.54, consensus $1.60 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 05

    Jun

  • 13

    Jun

NBIX

Neurocrine

$76.64

-2.39 (-3.02%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Initiation
Neurocrine initiated  »

Neurocrine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

CNS

Cohen & Steers

$50.01

-0.275 (-0.55%)

, TROW

T. Rowe Price

$104.18

-0.24 (-0.23%)

16:31
05/20/19
05/20
16:31
05/20/19
16:31
Hot Stocks
Cohen & Steers names Paul Zettl chief marketing officer »

Paul Zettl has joined…

CNS

Cohen & Steers

$50.01

-0.275 (-0.55%)

TROW

T. Rowe Price

$104.18

-0.24 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Jun

16:30
05/20/19
05/20
16:30
05/20/19
16:30
Options
Preliminary option volume of 17.5M today »

Preliminary option volume…

VRTX

Vertex

$165.71

-2.97 (-1.76%)

16:29
05/20/19
05/20
16:29
05/20/19
16:29
Initiation
Vertex initiated at Credit Suisse »

Vertex initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

ASNA

Ascena Retail

$1.13

-0.125 (-9.96%)

16:28
05/20/19
05/20
16:28
05/20/19
16:28
Hot Stocks
Ascena Retail announces wind down of Dressbarn »

Ascena Retail announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GILD

Gilead

$65.85

-0.49 (-0.74%)

16:26
05/20/19
05/20
16:26
05/20/19
16:26
Initiation
Gilead initiated at Credit Suisse »

Gilead initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

BIIB

Biogen

$230.70

1.49 (0.65%)

16:24
05/20/19
05/20
16:24
05/20/19
16:24
Initiation
Biogen initiated at Credit Suisse »

Biogen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

SWI

SolarWinds

$19.16

0.04 (0.21%)

16:23
05/20/19
05/20
16:23
05/20/19
16:23
Syndicate
SolarWinds files to sell 17.25M shares of common stock »

JPMorgan, Goldman Sachs,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 23

    May

AMGN

Amgen

$168.36

-1.5 (-0.88%)

16:21
05/20/19
05/20
16:21
05/20/19
16:21
Initiation
Amgen initiated at Credit Suisse »

Amgen initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 31

    May

GM

General Motors

$36.98

-0.02 (-0.05%)

16:21
05/20/19
05/20
16:21
05/20/19
16:21
Periodicals
GM plans wind-down of Maven car-sharing service in some cities, WSJ says »

According to the Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 04

    Jun

  • 05

    Jun

  • 01

    Aug

DBVT

DBV Technologies

$8.98

-0.21 (-2.29%)

, AIMT

Aimmune

$19.68

-0.41 (-2.04%)

16:20
05/20/19
05/20
16:20
05/20/19
16:20
Initiation
DBV Technologies, Aimmune initiated  »

Aimmune assumed with an…

DBVT

DBV Technologies

$8.98

-0.21 (-2.29%)

AIMT

Aimmune

$19.68

-0.41 (-2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 13

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.